<DOC>
	<DOCNO>NCT01885728</DOCNO>
	<brief_summary>The primary objective study characterize immune-modulatory effect arginine-rich nutritional supplement patient undergo surgery . Numerical functional change circulate immune cell assess mass cytometry .</brief_summary>
	<brief_title>Immune-modulation Effects Arginine Rich Nutritional Supplement Surgical Patients</brief_title>
	<detailed_description />
	<criteria>1 . Colon surgery cancer 2 . Patients ≥ 18 ≤65 year age 3 . Patients willing able sign inform consent form Health Insurance Portability Act ( HIPAA ) authorization comply study procedures 1 . Patients immunesuppressant therapy within last 6 month ( e.g . azathioprine cyclosporine ) 2 . Patients pretreated ( 6 month ) currently chemotherapy cancer 3 . Patients radiation therapy ( within 6 month ) 4 . Patients chronic medication potential immunemodulatory effect ( e.g . daily oral morphineequivalent intake &gt; 30 mg ) 5 . Patients metastatic disease 6 . Patients active infectious disease ( within 2 month ) 7 . Patients significant metabolic disease ( e.g . diabetes type I ) 8 . Patients clinically significant organ dysfunction include renal hepatic dysfunction 9 . Patients significant cardiovascular respiratory comorbidities result impaired function frailty 10 . Patients autoimmune disease ( e.g . lupus ) 11 . Patients Hx substance abuse ( e.g. , alcoholism , drug dependency ) 12 . Undernourished patient indicate weight loss &gt; 10 % last 6 month 13 . Patients galactosemia 14 . Patients undergone previous major abdominal surgery 15 . Participation another clinical trial investigational drug device within last 30 day prior first day study , investigator 's opinion , would create increase risk participant compromise integrity either study 16 . Pregnancy 17 . Other condition compromise participant 's safety integrity study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>